Viracept

(Nelfinavir mesylate)

ApprovedSmall molecule

Nelfinavir mesylate is an antiviral medication used to treat HIV infection by helping to reduce the amount of HIV in the blood and slow down the progression of the disease.[2] Viracept is currently approved and in use across 5 indications[4].[1]

Viracept is one of 178 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

177

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionUnknown

LipodystrophyActive, not recruiting

HIV-1 InfectionUnknown

ESSCompleted

EffectivenessCompleted

HIV InfectionPreclinical

Unknown

LipodystrophyApproved

Active, not recruiting

HIV-1 InfectionPreclinical

Unknown

ESSPreclinical

Completed

EffectivenessPreclinical

Completed

Competition

Competitive Landscape

123 competitors in HIV Infection

#DrugCompanyPhaseTrials

Norvir

AbbVie

Approved

10 2

Tivicay

GSK

Approved

7 3

Olumiant

Eli Lilly

Approved

1 4

Viracept

AAgouron Pharmaceuticals

Approved

7 5

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

4 6

Agenerase

GGlaxo Dba Glaxosmithkline

Approved

4 7

Calciferol

Crestor

Istodax

Marinol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness17 trials

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002235·6 enrolled

Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002375·24 enrolled

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000922·1,710 enrolled

Show 14 more trials

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002211·160 enrolled

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Suspended·AAgouron Pharmaceuticals·Phase 2·NCT00004998·30 enrolled

A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002430·220 enrolled

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000914·800 enrolled

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

Suspended·AAgouron Pharmaceuticals·Phase 2·NCT00004999·350 enrolled

Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children

Unknown status· Gilead logo

Gilead·Phase 2·NCT00002219·36 enrolled

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002442

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Unknown status·AAgouron Pharmaceuticals·Phase 3·NCT00005002·688 enrolled

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001087·300 enrolled

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT00002381·24 enrolled

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001108·6 enrolled

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001091·200 enrolled

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Completed· Roche logo

Roche·Phase 1·NCT00002380·28 enrolled

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006441·398 enrolled

Drug12 trials

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Unknown status· GSK logo

GSK·Phase 3·NCT00009061·624 enrolled

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Completed· GSK logo

GSK·Phase 2·NCT00002423·100 enrolled

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00002240

Show 9 more trials

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000892·300 enrolled

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 4·NCT00005106·230 enrolled

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000912·475 enrolled

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002440·80 enrolled

A Study to Compare Two Different Anti-HIV Drug Regimens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000924·120 enrolled

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002411

A Study of 141W94 in Combination With Other Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 1·NCT00002372·48 enrolled

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00002429·500 enrolled

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00017758·56 enrolled

Treatment7 trials

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

Completed· GSK logo

GSK·N/A·NCT00002216

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000903·444 enrolled

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status·AAgouron Pharmaceuticals·Phase 4·NCT00005000·200 enrolled

Show 4 more trials

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Completed· Roche logo

Roche·Phase 3·NCT00002178·375 enrolled

A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

Completed·AAgouron Pharmaceuticals·Phase 2·NCT00006211·350 enrolled

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00028067·500 enrolled

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

HIV infection7 trials

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006443·24 enrolled

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000895·85 enrolled

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000872·55 enrolled

Show 4 more trials

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00017719·440 enrolled

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002177

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002176

HIV4 trials

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001094

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

Unknown status· GSK logo

GSK·Phase 3·NCT00008554·210 enrolled

A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients

Completed·AAbbott·N/A·NCT00002201

Show 1 more trial

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00002224·120 enrolled

33 more indications

Children3 trials

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000893·103 enrolled

Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

Completed·AAgouron Pharmaceuticals·Phase 1·NCT00002164·24 enrolled

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000913·50 enrolled

Interaction2 trials

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000898·18 enrolled

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000941·56 enrolled

HIV-12 trials

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002374·120 enrolled

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002378·825 enrolled

Drug Therapy2 trials

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

Completed·AAbbott·Phase 3·NCT00004583·660 enrolled

Pancreatic Cancer2 trials

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Completed·UUniversity of Nebraska·Phase 2·NCT01959672·11 enrolled

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Completed·UUniversity of Nebraska·Phase 1·NCT01068327·46 enrolled

Medication1 trial

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001122·74 enrolled

Liposarcoma1 trial

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Terminated·—·Phase 1/2·NCT00233948·29 enrolled

Double-blind1 trial

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

Completed·TTriangle Pharmaceuticals·N/A·NCT00002215

Kaposi's sarcoma1 trial

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003008·33 enrolled

Safety and Efficacy1 trial

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Completed· Gilead logo

Gilead·Phase 2·NCT00002184·120 enrolled

Women1 trial

A Study of Viracept in HIV-Positive Women

Completed·AAgouron Pharmaceuticals·Phase 2·NCT00002171

Completed· Roche logo

Roche·Phase 3·NCT00002397·24 enrolled

HIV-Infected Individuals1 trial

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled

Intensive Care1 trial

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled

Mycobacterium avium complex disease1 trial

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Completed·AAgouron Pharmaceuticals·Phase 2·NCT00002170

Hematologic Cancer1 trial

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Completed·SSwiss Cancer Institute·Phase 1·NCT01164709·18 enrolled

Solid Tumors1 trial

A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445106·28 enrolled

ESS1 trial

Viracept Expanded Access Program

Completed·AAgouron Pharmaceuticals·N/A·NCT00002165

Progesterone1 trial

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00016601·76 enrolled

Lipodystrophy1 trial

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00006190

Combination Therapy1 trial

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

Completed·AAgouron Pharmaceuticals·Phase 2·NCT00004985·75 enrolled

Tuberculosis1 trial

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00004736·44 enrolled

Pregnant Women1 trial

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000887·24 enrolled

Pregnancy1 trial

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Completed· Pfizer logo

Pfizer·Phase 4·NCT00246610·16 enrolled

Kidney Cancer1 trial

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Terminated·UUniversity of Washington·Phase 2·NCT03050060·21 enrolled

Kaposi Sarcoma1 trial

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT03077451·36 enrolled

Non-Small Cell Lung Cancer1 trial

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Completed·—·Phase 1/2·NCT00589056·55 enrolled

Randomized1 trial

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Completed·AAgouron Pharmaceuticals·Phase 2·NCT00002185·20 enrolled

Multiple Myeloma1 trial

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 1·NCT03829020·9 enrolled

Cytomegalovirus Retinitis1 trial

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

Completed·AAgouron Pharmaceuticals·Phase 2·NCT00002169

Glioblastoma Multiforme1 trial

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Terminated·—·Phase 1·NCT00915694·15 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 14, 1997

VIRACEPT

NDA NDA020779

Jun 4, 1997

VIRACEPT

NDA NDA020779

Jul 31, 1997

VIRACEPT

NDA NDA020779

Aug 29, 1997

VIRACEPT

NDA NDA020779

Aug 29, 1997

VIRACEPT

NDA NDA020779

Sep 30, 1997

VIRACEPT

NDA NDA020779

Nov 21, 1997

VIRACEPT

NDA NDA020779

Nov 21, 1997

VIRACEPT

NDA NDA020779

Nov 26, 1997

VIRACEPT

NDA NDA020779

Feb 3, 1998

VIRACEPT

NDA NDA020779

May 4, 1998

VIRACEPT

NDA NDA020779

May 4, 1998

VIRACEPT

NDA NDA020779

Jun 5, 1998

VIRACEPT

NDA NDA020779

Jun 12, 1998

VIRACEPT

NDA NDA020779

Jul 17, 1998

VIRACEPT

NDA NDA020779

Sep 14, 1998

VIRACEPT

NDA NDA020779

Oct 30, 1998

VIRACEPT

NDA NDA020779

Dec 1, 1998

VIRACEPT

NDA NDA020779

Mar 19, 1999

VIRACEPT

NDA NDA020779

May 25, 1999

VIRACEPT

NDA NDA020779

Jul 16, 1999

VIRACEPT

NDA NDA020779

Aug 6, 1999

VIRACEPT

NDA NDA020779

Aug 17, 1999

VIRACEPT

NDA NDA020779

Nov 24, 1999

VIRACEPT

NDA NDA020779

Nov 24, 1999

VIRACEPT

NDA NDA020779

Feb 7, 2000

VIRACEPT

NDA NDA020779

Mar 28, 2000

VIRACEPT

NDA NDA020779

May 17, 2000

VIRACEPT

NDA NDA020779

Sep 15, 2000

VIRACEPT

NDA NDA020779

Nov 8, 2000

VIRACEPT

NDA NDA020779

Apr 5, 2001

VIRACEPT

NDA NDA020779

Jun 19, 2001

VIRACEPT

NDA NDA020779

Sep 28, 2001

VIRACEPT

NDA NDA020779

Oct 26, 2001

VIRACEPT

NDA NDA020779

Oct 26, 2001

VIRACEPT

NDA NDA020779

Feb 5, 2002

VIRACEPT

NDA NDA020779

Feb 5, 2002

VIRACEPT

NDA NDA020779

Dec 20, 2002

VIRACEPT

NDA NDA020779

Apr 30, 2003

VIRACEPT

NDA NDA021503

Aug 27, 2003

VIRACEPT

NDA NDA020779

Aug 27, 2003

VIRACEPT

NDA NDA021503

Mar 19, 2004

VIRACEPT

NDA NDA020779

Jun 4, 2004

VIRACEPT

NDA NDA020779

Jun 4, 2004

VIRACEPT

NDA NDA021503

Sep 28, 2005

VIRACEPT

NDA NDA020779

Sep 28, 2005

VIRACEPT

NDA NDA021503

Dec 22, 2006

VIRACEPT

NDA NDA021503

Dec 22, 2006

VIRACEPT

NDA NDA020779

Jul 31, 2007

VIRACEPT

NDA NDA021503

Jul 31, 2007

VIRACEPT

NDA NDA020779

Feb 13, 2008

VIRACEPT

NDA NDA020779

Feb 13, 2008

VIRACEPT

NDA NDA021503

Nov 25, 2008

VIRACEPT

NDA NDA020779

Nov 25, 2008

VIRACEPT

NDA NDA021503

Apr 26, 2010

VIRACEPT

NDA NDA021503

Apr 26, 2010

VIRACEPT

NDA NDA020779

Apr 26, 2010

VIRACEPT

NDA NDA021503

Apr 26, 2010

VIRACEPT

NDA NDA020779

Feb 25, 2011

VIRACEPT

NDA NDA020779

Feb 25, 2011

VIRACEPT

NDA NDA021503

Feb 17, 2012

VIRACEPT

NDA NDA020779

Feb 17, 2012

VIRACEPT

NDA NDA021503

Apr 6, 2012

VIRACEPT

NDA NDA021503

Apr 6, 2012

VIRACEPT

NDA NDA020779

May 28, 2013

VIRACEPT

NDA NDA021503

May 28, 2013

VIRACEPT

NDA NDA020779

Mar 27, 2015

VIRACEPT

NDA NDA020779

Mar 27, 2015

VIRACEPT

NDA NDA021503

Sep 15, 2016

VIRACEPT

NDA NDA020779

Sep 15, 2016

VIRACEPT

NDA NDA021503

Mar 24, 2021

VIRACEPT

NDA NDA021503

Mar 24, 2021

VIRACEPT

NDA NDA020779

Sources

References

[1]
ClinicalTrials.gov — 86 trial records for Nelfinavir mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Viracept drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Nelfinavir mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Nelfinavir mesylate. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021503). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Agouron Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Protease Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAgouron Pharmaceuticals

Viracept

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness17 trials

Drug12 trials

Treatment7 trials

HIV infection7 trials

HIV4 trials

Children3 trials

Interaction2 trials

HIV-12 trials

Drug Therapy2 trials

Pancreatic Cancer2 trials

Medication1 trial

Liposarcoma1 trial

Double-blind1 trial

Kaposi's sarcoma1 trial

Safety and Efficacy1 trial

Women1 trial

Chemotherapy1 trial

Drug Interactions1 trial

Kidney Disease1 trial

HIV-Infected Individuals1 trial

Intensive Care1 trial

Mycobacterium avium complex disease1 trial

Hematologic Cancer1 trial

Solid Tumors1 trial

ESS1 trial

Progesterone1 trial

Lipodystrophy1 trial

Combination Therapy1 trial

Tuberculosis1 trial

Pregnant Women1 trial

Pregnancy1 trial

Kidney Cancer1 trial

Kaposi Sarcoma1 trial

Non-Small Cell Lung Cancer1 trial

Randomized1 trial

Multiple Myeloma1 trial

Cytomegalovirus Retinitis1 trial

Glioblastoma Multiforme1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News